AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02481791
Drug: Remifentanil and/or propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
Trial: NCT02481791
Drug: Remifentanil and/or propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
Trial: NCT00909506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: Receive placebo pill once every evening on 1\~2 weeks.~Receive placebo pill in every morning and evening on 3\~24 weeks (twice a day).
Trial: NCT00988988
Drug: 1% Steroid Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparing to AGEE cream or placebo. 1% steroid cream is available over the counter. To be used immediately after injection and as needed.
Trial: NCT01105936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo caplets
Trial: NCT04921657
Drug: Rosuvastatin 10mg
RxNorm normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01841489
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg GS-9973 (Formulation 1)
Trial: NCT01841489
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
Trial: NCT01841489
Drug: Treatment G
RxNorm normalized name: VanaLice Lice Killing Treatment Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg GS-9973 (Reference formulation)
Trial: NCT01841489
Drug: Treatment H
RxNorm normalized name: Walgreens Lice Treatment Homeopathic Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
Trial: NCT01841489
Drug: Treatment I
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
Trial: NCT00988988
Drug: topical placebo cream with no active ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream to be applied immediately after injection and repeated as needed.
Trial: NCT03329846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified day
Trial: NCT01144091
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
Trial: NCT00446641
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 1 tablet twice a day matching for cilostazol
Trial: NCT01243723
Drug: Eductyl suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One suppository every morning during 21 days
Trial: NCT01243723
Drug: Placebo suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One suppository every morning during 21 days
Trial: NCT03066193
Drug: Dronabinol and Palmitoylethanolamide
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
Trial: NCT04112303
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT00080301
Drug: Ixabepilone + Capecitabine
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity~Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
Trial: NCT00080301
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
Trial: NCT00496379
Drug: ZK219477
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously over approximately 30 minutes once every 3 weeks
Trial: NCT03787550
Drug: The Sedatives, analgesics and antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.
Trial: NCT01934868
Drug: prolotherapy solution of 20% dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
Trial: NCT02414919
Drug: ParaGard
RxNorm normalized name: ParaGard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper T380A
Trial: NCT02278861
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin - 10mg/day (one pill) after lunch for six months
Trial: NCT02278861
Drug: Tretinoin 0,05% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
Trial: NCT02598440
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants wil receive once-monthly oral ibandronate (150 mg tablet)
Trial: NCT01729819
Drug: Placebo orally disintegrating tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04096144
Drug: Neuromuscular Blocking Agents
RxNorm normalized name: NEUROMUSCULAR BLOCKING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.
Trial: NCT02393937
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are assigned to one of three groups in parallel for the duration of the study
Trial: NCT01818596
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
Trial: NCT01801774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01784250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic a drug
Trial: NCT00744731
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 1 week
Trial: NCT00488059
Drug: Optimized background ARV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00061893
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. \[Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.\] .
Trial: NCT00061893
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV, 1200 mg/m2 IV infusion over 1 hour with MESNA uroprotection, on Day 1. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
Trial: NCT00061893
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV, Doxorubicin 75 mg/ m2 /course continuous IV infusion over 48 hours, beginning Day 1. Note: The total doxorubicin dose per cycle is 75 mg/ m2, which will be given as 37.5 mg/m2/day x 2 days. Doxorubicin may be given as a continuous infusion or brief infusion.
Trial: NCT00666939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo 30 minutes prior to bedtime
Trial: NCT03967847
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Ketorolac
Trial: NCT03669562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion liposome control
Trial: NCT00135525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01047436
Drug: Artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
Trial: NCT04539262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an aerosolized solution
Trial: NCT00377455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
Trial: NCT00309452
Drug: Medications
RxNorm normalized name: AUTONOMIC MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.
Trial: NCT01678313
Drug: Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)
RxNorm normalized name: doxazosin 4 MG
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study group
Trial: NCT02640755
Drug: Multiple dose AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual TORC1/TORC2 inhibitor
Trial: NCT04159701
Drug: LY3454738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04159701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00765804
Drug: EGP-437 with EyeGate® II System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System
Trial: NCT03731091
Drug: Enstilar® foam (LEO Pharma Inc.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 4 weeks (28 days)
Trial: NCT03738137
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sufentanil is applied.
Trial: NCT03301350
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.
Trial: NCT03301350
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.
Trial: NCT03465007
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: we will give IV Hydrocortisone 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD treatments.
Trial: NCT03465007
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: we will give IV normal saline 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD
Trial: NCT00771667
Drug: Placebo (IP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction phase (Week 0-8) (IP) - Placebo IV group
Trial: NCT00771667
Drug: Placebo IV - Responder - Placebo SC (MP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
Trial: NCT00664846
Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical Management,including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
Trial: NCT01024920
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGF inhibitor
Trial: NCT00664846
Drug: Asprin / Clopidogrel, Atorvastatin / Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
Trial: NCT02090309
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.
Trial: NCT02090309
Drug: normal saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection of 5 ml normal saline 0.9% as a single bolus.
Trial: NCT04097080
Drug: NBTX-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug group will receive 6 doses of NBTX-001 given three times a week.
Trial: NCT04097080
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group will receive reconstituted air given three times a week.
Trial: NCT01554189
Drug: MK-8325
RxNorm normalized name: vitamin MK 7
DrugBank: MK-8245 (DB13024)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)
Trial: NCT01554189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match MK-8325 capsules, orally, once per day for 5 days
Trial: NCT04618744
Drug: ORMD-0801 (Insulin) capsule 8 mg BD
RxNorm normalized name: insulin, regular, human 8 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg ORMD-0801, 1 capsule, twice a day, once in the morning and once in the evening.
Trial: NCT01613495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
Trial: NCT01606969
Drug: scalp infiltration solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
Trial: NCT01606969
Drug: scalp infiltration solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
Trial: NCT02611817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab placebo-matching SC injection.
Trial: NCT01315899
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given once as a single dose during the study as per Williams crossover design
Trial: NCT02685306
Drug: Taxane
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
Trial: NCT02942758
Drug: standard-dose AZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
Trial: NCT00584012
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03874156
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS
Trial: NCT00088673
Drug: 3APS
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01764451
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03121807
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03121807
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02541500
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
Trial: NCT02017704
Drug: capecitabine and IMRT (if randomized to this arm)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
Trial: NCT02017704
Drug: FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~* 5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion.
Trial: NCT04329325
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Please see detailed summary.
Trial: NCT05267938
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated
Trial: NCT00781404
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
Trial: NCT00565006
Drug: MK0859
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03011775
Drug: Acetylsalicylic Acid 75Mg Tablet
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet per a day
Trial: NCT03011775
Drug: Rosuvastatin Calcium 20 MG Oral Tablet
RxNorm normalized name: ROSUVASTATIN CALCIUM 20 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet per a day
Trial: NCT02993471
Drug: Drug Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01263444
Drug: Habitual prostaglandin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular therapy used daily as prescribed
Trial: NCT00474006
Drug: arm II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days